Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
Follow AKAN
Akanda Corp. (AKAN) Beneish M-score
Akanda Corp.'s Beneish M-score for fiscal 2025 cannot be worked out: gross margin index cannot be worked out.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2024 | −0.76 | 0.27 |
| FY2023 | −1.04 | (53.94) |
| FY2022 | 52.90 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 5.52 | — | 5.08 | |
| Gross margin index | — | — | n/a | — |
| Asset quality index | 0.56 | — | 0.23 | |
| Sales growth index | 0.31 | — | 0.28 | |
| Depreciation index | 0.95 | — | 0.11 | |
| SG&A index | 6.27 | — | −1.08 | |
| Total accruals to total assets | (6.56) | — | −30.69 | |
| Leverage index | 6.39 | — | −2.09 | |
| Beneish M-score | n/a — gross margin index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| RDHL Redhill Biopharma Ltd. compare | −8.7× |
| IMCC IM Cannabis Corp. compare | −5.4× |
| YCBD cbdMD, Inc. compare | −2.5× |
| SNOA Sonoma Pharmaceuticals, Inc. compare | −1.7× |
| GELS Gelteq Limited compare | −0.7× |
| BTAIQ BioXcel Therapeutics, Inc. compare | −0.6× |
| AKAN Akanda Corp. | — |
| APUS Apimeds Pharmaceuticals US, Inc. compare | — |
| PRFX PainReform Ltd. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI